| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754551 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 8 Pages |
Abstract
Salirasib was well tolerated and showed modest activity in relapsed/refractory hematological malignancies. The safety profile of Salirasib and its hematological malignancy relevant target makes it a potential drug to be used in combination therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Talha Badar, Jorge E. Cortes, Farhad Ravandi, Susan O'Brien, Srdan Verstovsek, Guillermo Garcia-Manero, Hagop Kantarjian, Gautam Borthakur,